INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape. "Our collaboration with OpenAI represents a groundbreaking step forward in the...Read more
VICTORIA, British Columbia / Jun 25, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating with PGxAI to leverage BioStrand's patented Foundation AI Model, LENSai. This collaboration advances the precision medicine field of pharmacogenomics and supports LENSai Application...Read more
Toronto, Ontario – TheNewswire - June 24, 2024 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has been selected to present its AI-enhanced cardiac ultrasound technology, which generates MRI-quality cardiac measurements in minutes, to health-care leaders at The Data Effect on June 25th in Vancouver. CEO Hugh MacNaught will be on the panel Accelerating AI Startups in Canadian Health Care, which...Read more
PURCHASE, NY, June 24, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, released new data today from two studies, presented at the American Diabetes Association’s 84th Scientific Sessions, that illustrate the company’s unmatched predictive modeling capabilities to help members with type 2 diabetes control their blood sugar through participation in Teladoc Health’s diabetes management...Read more
Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to...Read more
Pentavere collaborated with Princess Margaret Cancer Centre's Radiation Oncology Department to assess the feasibility and accuracy of DARWEN™ AI to find patients experiencing radiation related toxicities based on information retrieved from electronic health records. The data and results from this groundbreaking AI research collaboration have been accepted for presentation at the American Society for Radiation Oncology in Washington DC...Read more
SAN FRANCISCO, June 20, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, announced today that Emergency Services Inc., a physician-owned emergency medicine services group in Columbus, Ohio, is introducing Augmedix Go ED to physicians in the emergency department (ED) at the second-largest healthcare system in central Ohio. Augmedix Go ED is the industry’s first fully...Read more
RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory...Read more
Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels...Read more
Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications PLEASANTON, Calif., June 13, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing. The Company recently released an engineering accuracy study directed by Movano Health...Read more
Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place...Read more
DURHAM, N.C. and WARSAW, Ind., June 12, 2024 /PRNewswire/ -- RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions that advance value-based orthopedic care and health equity. During the multi-year agreement, Zimmer Biomet will commercialize RevelAi...Read more
HEALWELL enters into an agreement to acquire VeroSource Solutions Inc. and its end-to-end, customizable, cloud-based platform that enables patients, care providers and administrators to seamlessly access and interact with healthcare data. VeroSource currently serves five provincial health clients and is expected to generate over $8 million in revenues in 2024 with an expected EBITDA1 margin of over 10%. Historically, VeroSource has...Read more
Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary data NEW YORK, June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia....Read more
BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. BioStrand’s novel software is rapidly and directly integrable into pharmaceutical, healthcare, and technology companies to enhance drug discovery capabilities. This proprietary software provides the...Read more
SINGAPORE, June 06, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announces the latest major update to its cloud-based MaNaDr AI-Powered Health Operating System (“MHOS”) designed to transform healthcare delivery on a global scale. Streamlined Operations, Enhanced Care The latest MHOS boasts a suite of powerful features that empower...Read more
Pentavere’s partnership with Takeda to pioneer real-world evidence analysis for HAE patients, addressing critical gaps in treatment understanding. This innovative research collaboration has generated one of the largest cohort data sets globally of HAE with normal C1 inhibitor and will be utilized in enhancing patient outcomes through better understanding of current treatment use and clinical outcomes. This partnership and commercial...Read more
Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service New AI capabilities available to patients who submit chest and abdominal CT scans for second opinions Offering the power of Artificial Intelligence to their second opinion CT report to promote early detection of chronic conditions PETACH TIKVA, Israel, June 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,”...Read more
Predictive Oncology’s organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture market is projected to grow by more than 14% annually, from $1.4 billion in 2022 to nearly $5.3 billion annually by 20321 PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics,...Read more
Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland VICTORIA, British Columbia / Jun 04, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that its Belgian subsidiary, BioStrand, is...Read more
Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's specialty condition management platform through AI-enabled clinical workflow automation Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics Acquisition expected to benefit health plans, clinicians, and members WASHINGTON, June 4, 2024 /PRNewswire/ -- Evolent Health,...Read more
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Jefferies Healthcare Conference - June 5-6, 2024 45th Annual Goldman Sachs Healthcare Conference - June 10-13, 2024 Morgan Stanley 3rd Annual Life Sciences AI Summit - June 26-27, 2024 About...Read more
Tempus, a leader in artificial intelligence and precision medicine, today announces a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus is now unveiling a collection of new and enhanced features designed to make it easier for clinicians to access each of their patient’s...Read more
Tempus, a leader in artificial intelligence and precision medicine, today announces a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus is now unveiling a collection of new and enhanced features designed to make it easier for clinicians to access each of their patient’s...Read more
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. This proximity bias, discoverable through...Read more
In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland, May 29, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to...Read more
Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces the successful completion of a Formative Human Factors study of its...Read more
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of...Read more
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. “I’m excited to bring my clinical and scientific expertise to...Read more
Pentavere partnered with Sunnybrook Health Sciences Centre to demonstrate how Pentavere’s DARWEN™ AI platform can help enhance cancer staging to improve patient outcomes. Results of this collaboration were presented at the prestigious American Head and Neck Society annual conference and published in JAMA Otolaryngology, which is the highest impact journal for Otolaryngologic or ‘head and neck’ cancers. This is the first published...Read more
Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office (IPO). To date,...Read more
New Data Presented at Heart Rhythm Society Conference Demonstrates Continued Progress with Company’s AI Program Data Show That Applying AI to VCG Data Provides More Consistent and Reliable Detection of Atrial Flutter SANTA CLARA, Calif. / May 20, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced new study...Read more
GAITHERSBURG, Md., May 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug discovery company using artificial intelligence (AI) and machine learning to enable the successful discovery and development of pharmaceuticals and biologics, today announced significant advancements in its collaboration with the Lieber Institute for Brain Development...Read more
HEAWELL AI’s Clinical Co-Pilot technology participated in recently published evidence showing the integration of a highly accurate machine model for Chronic Kidney Disease (“CKD”) progression when paired with Electronic Health Record (“EHR”) linked clinical decision support, improves guideline-recommended testing in patients with CKD. HEALWELL’s subsidiary Khure Health (“Khure”) co-authored an abstract that was published this month in...Read more
FORT MYERS, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s fastest-growing community oncology networks, and the AON Central Lab are pleased to announce the implementation of the new cytogenetics A.I. software HiBand v8.4 for karyogram segmentation and classification. AON Central Lab is the first laboratory in the world to utilize this technology. Cytogenetics A.I....Read more
SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVIDIA H100 Tensor Core GPUs interconnected by NVIDIA Quantum-2 InfiniBand networking. This NVIDIA-powered AI supercomputer...Read more
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform. On March...Read more
VMS+4.0 submitted to FDA on May 1 for clearance Ventripoint will market new advances after FDA clearance Toronto, Ontario – TheNewswire - May 6, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has reached another development milestone by submitting its next generation of software, VMS+4.0, to the U.S. Food and Drug Administration (“FDA”). This latest advance of...Read more
XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collaboration aims to refine and expand the positioning of XCE853, a novel protein disulfide isomerase (PDI) inhibitor, in new and targeted oncology indications,...Read more
WELL and HEALWELL AI have launched the second-generation of WELL AI Decision Support ("WAIDS"), which now features advanced chronic disease screening for diseases like chronic kidney disease, hypertension, and diabetes, enabling patient risk stratification. The updated WAIDS tool identifies over one hundred diseases and delivers actionable clinical insights at the point of care, contributing to the management of chronic...Read more
Company unveiling innovations which harness the power of AI to optimize the complex radiation therapy workflow and enable personalized, more timely care for patients across the cancer care continuum CHICAGO / May 01, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced Revolution RT,i a new radiation therapy computed tomography (CT) solution with innovative hardware and software solutions to help increase imaging...Read more
Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costs SECAUCUS, N.J. and BOSTON, May 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today...Read more
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo...Read more
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82% 690 subjects analyzed including previously unexamined and reported patients from Company’s ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm The power to determine advanced adenoma, lesions in a pre-cancerous...Read more
Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise CAMBRIDGE, MA AND SAN FRANCISCO, CA / ACCESSWIRE / April 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) and OpenAI today announced their ongoing collaboration to co-innovate with a shared...Read more
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry’s first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the country. The launch incorporates learnings from a pilot program with HCA...Read more
LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis (DVT) training application developed through a Butterfly Garden™ partnership with Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), a digital health company transforming care with the power of portable, semiconductor-based ultrasound...Read more
Integrated artificial intelligence (AI) and advanced tools improve image quality and exam speed to help providers make accurate diagnoses and tailor precision care for women Latest Voluson Signature ultrasound technology offers an intuitive and ergonomic design allowing clinicians to focus on patient care CHICAGO / Apr 18, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced the launch of the Voluson Signature 20 and 18...Read more
Advanced technology and support to enable the development of GenAI solutions PLEASANTON, Calif., April 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the Veeva AI Partner Program to provide partners with the advanced technology and support needed to integrate Generative AI (GenAI) solutions seamlessly with Veeva Vault applications. "Our customers are exploring GenAI solutions across many use cases...Read more
Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI chromosome karyotype...Read more
European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to support cancer diagnostics and treatment BOSTON and ROLLE, Switzerland, April 17, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory,...Read more
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This...Read more
Powered by digital pathology and AI algorithms, Patholytix Foresight drives speed and quality in toxicologic pathology practices WILMINGTON, Mass. & DUBLIN / Apr 11, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology...Read more
Insights open the door for potential precision immunotherapy innovation targeting novel pathways and patient enrichment strategies with the potential to improve clinical trial success rates TORONTO, April 10, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces the presentation of new data...Read more
AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy DUBLIN, April 10, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along...Read more
Ginkgo epidemiological modeling experts and Northeastern University researchers awarded new grant from the Bill & Melinda Gates Foundation BOSTON, April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has been awarded a grant from the Bill & Melinda Gates Foundation to build an open-access, AI-enabled measles forecasting...Read more
New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company’s Deep Learning Technology Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables SANTA CLARA, Calif. / Apr 09, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company...Read more
Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation Expands access to iCAD’s AI-powered ProFound Breast Health Suite and Densitas’ AI solutions to patients and medical professionals worldwide NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a...Read more
SAN FRANCISCO and ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- In a significant move to streamline healthcare workflows and allow clinicians to focus on patient care, Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, announced today that it has integrated with Andor Health, an AI-first cloud-based communication and collaboration platform for virtual care. The alliance aims to harness the power...Read more
NASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its AI-powered solution effectively uncovers calcium deposits in the breast vessels, a sign of possible cardiovascular disease in women. iCAD research collaborator Chirag Parghi, M.D., Chief Medical Officer of Solis Mammography, presented the...Read more
CALGARY, AB, April 4, 2024 /CNW/ - Nanalysis Scientific Corp. ("the Company" or "Nanalysis", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR machines, MRI technology for industrial and research applications, and detection equipment services, announces that its subsidiary Nanalysis Corp. is receiving advisory services and up to $1.45 million in non-repayable, non-dilutive funding from the National Research Council...Read more
Virtual Care Suite (VCS) is now available to license in the United States for providers offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices US product launch to kick off at the Obesity Medicine Conference in Denver on April 25 NATICK, Mass. / Apr 04, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial...Read more
PLEASANTON, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leading provider of healthcare IT solutions, is thrilled to announce its partnership with Cynomi, a pioneer vCISO platform vendor. This collaboration introduces an innovative Virtual Chief Information Security Officer (vCISO) service tailored specifically for the healthcare provider market,...Read more
Pentavere has published industry’s first peer-reviewed paper utilizing AI and large language models (or LLMs) to identify rare lung cancer patients. Industry applications may include Real World Evidence generation, identification of areas of unmet clinical need and optimization of cancer therapy and care pathways. Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using...Read more
Caption AI on Vscan Air SL expands access to cardiac care by enabling more medical professionals to feel confident acquiring images for rapid assessments AutoEF feature automatically calculates ejection fraction, saving time for clinicians while delivering key information for making their diagnoses GE HealthCare to debut new technology at 2024 American College of Cardiology Annual Scientific Session & Expo, April 6 – 8, 2024 in...Read more
PLEASANTON, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), In a pioneering move, a leading health system has partnered with Healthcare Triangle to utilize a groundbreaking cloud-based AI and machine learning solution. This collaboration establishes a revolutionary benchmark in the management and utilization of patient data, ultimately elevating the...Read more
NASHUA, N.H., April 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International. RAD-AID, a non-profit charitable organization dedicated to improving radiology healthcare in medically underserved regions, is collaborating with iCAD to introduce mammography AI-based decision...Read more
NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud. The innovative Software-as-a-Service (SaaS) platform provides medical providers with a cost-effective, secure, and scalable means to access and deploy the latest ProFound Breast Health Suite of AI solutions. “With the commercial...Read more
VICTORIA, British Columbia / Mar 28, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company,...Read more
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce a strategic evolution in its business model that will place the Company at the forefront of artificial intelligence-driven...Read more
Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has...Read more
Prostate Volume Assist (PVA) is the company’s proprietary urology-based artificial intelligence (AI) software feature designed to automate the manual process for generating prostate volume measurements New AI software feature will be available for use on the bkActiv, bk3000/5000 and bkSpecto active imaging systems Addition of AI solution advances leadership in urological active imaging CHICAGO / Mar 27, 2024 / Business Wire / GE...Read more
Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration Company to host webcasted conference...Read more
CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new...Read more
MIAMI / Mar 21, 2024 / Business Wire / Ontrak Health (NASDAQ: OTRK), a leading AI-powered and tech-enabled behavioral healthcare company, today announced the launch of its Ontrak Advanced Engagement System. This system integrates Augmented Intelligence (AI) with an evidence-based clinical framework to deliver human-centered, personalized member engagement. Built on a foundation of real-world AI application, the Ontrak Advanced Engagement...Read more
Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENSai™. VICTORIA, British Columbia / Mar 20, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA® instrument platform from Carterra®, a leading provider of...Read more
Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Status Please see important safety information below NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug...Read more
Using NVIDIA Technology, SonoSAMTrack¹ demonstrates its pliability and applicability in ultrasound image segmentation, consistently delivering high-quality results over a wide range of demanding datasets and conditions SAN JOSE, Calif. / Mar 18, 2024 / Business Wire / Building on a long-term artificial intelligence (AI) collaboration, GE HealthCare used NVIDIA technology to develop its recent research model SonoSAMTrack1, which...Read more
BALTIMORE, March 14, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions, today highlighted its use of computer-aided testing in a pre-clinical setting...Read more
HEALWELL AI has signed services agreements with both WELL Health USA and U.S. based Circle Medical Technologies Inc., which expands its footprint in the U.S. and will enable U.S. healthcare providers with a suite of artificial intelligence (AI) powered preventative care solutions. HEALWELL’s Pentavere Research Group Inc. has partnered with WELL Health USA’s CRH Medical to access U.S. clinical data to gain insights in supporting...Read more
VANCOUVER, BC, March 13, 2024 /CNW/ - In a recent presentation to the US Biophysical Society in Philadelphia1, Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) CEO Dr. Bob Hancock announced how the ground-breaking use of artificial intelligence (AI) has allowed the development of new and improved treatments for biofilm infections. Biofilms are communities of bacteria that infect...Read more
ORLANDO, Fla. / Mar 12, 2024 / Business Wire / Based on its long-term artificial intelligence (AI) partnership, GE HealthCare and Mass General Brigham plan to integrate medical imaging foundation models into their AI research work, with a strong focus on responsible AI practices. Both organizations have been working closely on AI solutions since announcing their 10-year commitment in 2017 to explore the use of AI across a broad range of...Read more
Biotricity's AI automation engine has already proven to increase operational efficiency and support growth, evidenced by the Company's recent margin improvement The Healthcare AI Market is projected to soar to $208.2 billion and remote patient monitoring (RPM) market anticipated to reach $96.67 billion by 2030 Biotricity is now expanding its Cardiac AI platform, building anonymized clinical models to support clinical decisions with...Read more
According to early findings in the ADOPT study, Nanox.AI software improves detection of key risk factor for osteoporosis, outperforming UK National Health Service national average Findings demonstrate real-world impact of integrating AI technology in routine chest and abdomen CT scans to improve detection of spine fracture, an early sign of osteoporosis PETACH TIKVA, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD...Read more
NetraMark's NetraAI is tasked with identifying inclusion and exclusion criteria that are predicted to drive larger effect and smaller placebo responses in future clinical trials Potential to demonstrate statistically significant efficacy results in future trials using fewer patients and reduce the time and cost needed for product approval TORONTO, March 12, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or...Read more
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. ("MitoCareX "), the Company’s...Read more
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced new positive data and product enhancements for Augmedix Go, its ambient AI medical documentation product. Now supporting over 50 medical specialties, the Augmedix Go mobile app optimizes ambient AI technology to produce comprehensive draft medical notes in real time by processing the...Read more
Novel machine learning (ML) approach identifies genetic drivers within specific Parkinson's disease (PD) patient subpopulations and uncovers pivotal disease pathways, enhancing understanding of disease and treatment strategies Data presented at the International Conference on Alzheimer's and Parkinson's Diseases and...Read more
Booth (#2500) will showcase AI-enabled innovations and digital solutions that enhance clinical decision making and provide personalized patient care ORLANDO, Fla. / Mar 07, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) will showcase its industry-leading portfolio of artificial intelligence (AI)-enabled medical devices and digital solutions in Booth 2500 at the Health Information and Management Systems Society (HIMSS) Global...Read more
Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next week at the HIMSS24 conference in Orlando, Florida VICTORIA, British Columbia / Mar 07, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced the development of a Foundation AI Model that...Read more
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE